Home › Companies › ORKA

Oruka Therapeutics, Inc.

ORKA Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Dermatology Immunology Protein

Most recent annual filing: 2026-03-12

Pipeline (6 active programs)

ORKA-001

Protein Target: IL-23p19

Psoriasis Phase 1 subcutaneous Paragon Therapeutics

ORKA-002

Protein Target: IL-17A, IL-17F

Psoriasis Phase 2 subcutaneous Paragon Therapeutics
Hidradenitis Suppurativa Phase 2 Paragon Therapeutics
Psoriatic Arthritis Phase 2 Paragon Therapeutics

ORKA-021

Protein Target: IL-17A, IL-17F, IL-23p19

Psoriasis

ORKA-003

Undisclosed indication Preclinical

Technology platforms

Hypercon · Halozyme

Halozyme's Hypercon microparticle technology enabling hyperconcentration of drugs and biologics to reduce injection volume and support patient-friendly administration; licensed by Oruka for IL-23p19 in psoriatic disease and up to one additional target

Targets: IL-23p19

Biotech Distilled coverage (1)

2026-05-13 Oruka Therapeutics (ORKA) - Scientific Deep Dive for ORKA-001, ORKA-002, and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.